Quantcast

Latest Auxilium Pharmaceuticals Inc. Stories

2014-08-11 16:27:52

LYNBROOK, N.Y., Aug. 11, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX(®) (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX(®) in the EU, today announced its financial results for the second quarter ended June 30, 2014 and provided a corporate update. "This was a momentous quarter of milestones for XIAFLEX both commercially and clinically. We saw...

2014-08-11 08:27:52

CHESTERBROOK, Pa., Aug. 11, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, announced that Andrew Saik will be appointed Chief Financial Officer, effective August 18, 2014. Mr. Saik will be responsible for all financial and information technology activities and relationships and will play a critical leadership role in executing Auxilium's diversification and growth strategy. "Andrew brings nearly 20 years...

2014-07-31 16:29:32

-Company to Host Conference Call That Day at 8:30 a.m. ET- CHESTERBROOK, Pa., July 31, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that the Company will release results for the second quarter of 2014 on Thursday, August 7, 2014 before the opening of the U.S. financial markets. The Company also will conduct a conference call that day at 8:30 a.m. ET to discuss results and highlights of the...

2014-07-31 08:34:32

Acceptance of Regulatory Submission Triggers $10 Million Milestone Payment to Auxilium CHESTERBROOK, Pa., July 31, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that the Company will receive a $10 million regulatory milestone payment from its partner Asahi Kasei Pharma Corporation (Asahi Kasei). The payment is due because of the successful submission of a regulatory application to the Japanese Pharmaceutical...

2014-06-30 12:32:44

NEW YORK, June 30, 2014 /PRNewswire/ -- Levi & Korsinsky is investigating the Board of Directors of Auxilium Pharmaceuticals Inc. ("Auxilium" or "the Company") (NasdaqGS: AUXL) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to QLT Inc. (NasdaqGS: QLTI). http://photos.prnewswire.com/prnvar/20120409/MM84375LOGO Click here to learn more about the investigation: http://zlk.9nl.com/auxilium-pharmaceuticals-auxl, or...

2014-06-26 08:27:14

Accelerates Auxilium's Ongoing Transformation Into Leading North American Specialty Biopharmaceutical Company CHESTERBROOK, Pa. and VANCOUVER, Canada, June 26, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, and QLT Inc. (NASDAQ: QLTI) (TSX: QLT), a Canadian-based biotechnology company focused on developing innovative orphan ophthalmology products, today announced that they have entered into a definitive...

2014-06-25 16:26:44

LYNBROOK, N.Y., June 25, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX(®) in the U.S. and XIAPEX(®) in the EU, announced today that Swedish Orphan Biovitrum AB (Sobi) has filed for an extension of the label for XIAPEX (the EU trade name for collagenase clostridium histolyticum or CCH) with the European Medicines Agency (EMA) to include the indication of...

2014-06-25 08:31:00

STOCKHOLM and CHESTERBROOK, Pa., June 25, 2014 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi) and Auxilium Pharmaceuticals, Inc. today announced that Sobi has filed for an extension of the label for Xiapex® (collagenase clostridium histolyticum) with the European Medicines Agency (EMA) to include the indication of Peyronie's disease. The filing is based on positive safety and efficacy outcome data from two double-blind placebo-controlled studies, IMPRESS I and II (The...

2014-06-11 08:28:34

CHESTERBROOK, Pa., June 11, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that it has partnered with Prasco, LLC ("Prasco") to introduce an Authorized Generic version of Testim(®) (testosterone gel). Prasco has product inventory available and has commenced shipping product. Testim and its Authorized Generic version are testosterone gels approved by the U.S. Food and Drug Administration to treat...

2014-06-02 16:26:58

CHESTERBROOK, Pa., June 2, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that James E. Fickenscher, Chief Financial Officer, is leaving the Company to pursue other interests. Mr. Fickenscher will continue in his current role through August 15, 2014. "The Board and I want to thank Jim for his nine years of service and important contributions to the evolution of Auxilium," said Adrian Adams,...


Word of the Day
humgruffin
  • A terrible or repulsive person.
Regarding the etymology of 'humgruffin,' the OED says (rather unhelpfully) that it's a 'made-up word.' We might guess that 'hum' comes from 'humbug' or possibly 'hum' meaning 'a disagreeable smell,' while 'gruffin' could be a combination of 'gruff' and 'griffin.'